Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.
OBJECTIVE
To develop guidelines for selection of antiepileptic drugs (AEDs) among people with HIV/AIDS.


METHODS
The literature was systematically reviewed to assess the global burden of relevant comorbid entities, to determine the number of patients who potentially utilize AEDs and antiretroviral agents (ARVs), and to address AED-ARV interactions.


CONCLUSIONS
AED-ARV administration may be indicated in up to 55% of people taking ARVs. Patients receiving phenytoin may require a lopinavir/ritonavir dosage increase of ~50% to maintain unchanged serum concentrations (Level C). Patients receiving valproic acid may require a zidovudine dosage reduction to maintain unchanged serum zidovudine concentrations (Level C). Coadministration of valproic acid and efavirenz may not require efavirenz dosage adjustment (Level C). Patients receiving ritonavir/atazanavir may require a lamotrigine dosage increase of ∼50% to maintain unchanged lamotrigine serum concentrations (Level C). Coadministration of raltegravir/atazanavir and lamotrigine may not require lamotrigine dosage adjustment (Level C). Coadministration of raltegravir and midazolam may not require midazolam dosage adjustment (Level C). Patients may be counseled that it is unclear whether dosage adjustment is necessary when other AEDs and ARVs are combined (Level U). It may be important to avoid enzyme-inducing AEDs in people on ARV regimens that include protease inhibitors or nonnucleoside reverse transcriptase inhibitors, as pharmacokinetic interactions may result in virologic failure, which has clinical implications for disease progression and development of ARV resistance. If such regimens are required for seizure control, patients may be monitored through pharmacokinetic assessments to ensure efficacy of the ARV regimen (Level C).
International Neurologic & Psychiatric Epidemiology Program, Michigan State University, East Lansing, USA. guidelines@aan.com
G L
GL
Birbeck
J A
JA
French
E
E
Perucca
D M
DM
Simpson
H
H
Fraimow
J M
JM
George
J F
JF
Okulicz
D B
DB
Clifford
H
H
Hachad
R H
RH
Levy
D000047:Academies and Institutes; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000592:standards* / Q000627:therapeutic use*; D002755:Choice Behavior; D016208:Databases, Factual / Q000706:statistics & numerical data; D004827:Epilepsy / Q000188:drug therapy* / Q000821:virology; D019317:Evidence-Based Medicine / Q000379:methods / Q000592:standards*; D006801:Humans; D014481:United States; D019562:Viral Load
D044966:Anti-Retroviral Agents; D000927:Anticonvulsants